Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-(1-methylethyl)-3-quinolin-6-yl‑1H‑pyrazolo[3,4‑d]pyrimidin‑4‑amine is an experimental small molecule compound containing a quinoline moiety fused to a pyrazolopyrimidine core. It has been studied as a potential inhibitor of the proto-oncogene tyrosine-protein kinase Src (SRC), which is involved in cell signaling pathways regulating proliferation and survival. The compound has not been approved for any indication and there are no reported clinical trials beyond preclinical or early research phases. Its mechanism of action is presumed to involve inhibition of SRC kinase activity based on structural similarity to other known SRC inhibitors and its listing as interacting with SRC in curated drug-target datasets[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine.